Citation

Papafragkakis H, Rao MS, Moehlen M, Dhillon S, Martin P. International Journal of Interferon, Cytokine and Mediator Research 2012; 4(1): 25-35.

Copyright

(Copyright © 2012)

DOI

10.2147/ijicmr.s28901

PMID

unavailable

Abstract

Interferon remains an essential component of treatment regimens for chronic hepatitis C infection. Mood disturbances, including depression, are relatively common in the hepatitis C virus-infected population and may worsen during hepatitis C treatment. Screening for depression prior to commencement of therapy is crucial and may improve treatment outcomes. Whether prophylactic antidepressant therapy should be initiated prior to therapy of hepatitis C virus infection with an interferon-based regimen remains unclear. We review the epidemiology, diagnosis, and management of depression before and during treatment of hepatitis C virus infection with interferon. © 2012 Papafragkakis et al.

Language: en

Keywords

human; Depression; insomnia; suicidal ideation; depression; prevalence; sex difference; anxiety; Suicide risk; major depression; suicidal behavior; Cytokines; pathogenesis; review; levothyroxine; kynurenine; serotonin; questionnaire; antidepressant agent; sexual dysfunction; citalopram; cognitive defect; paroxetine; sedation; serotonin uptake inhibitor; tricyclic antidepressant agent; sleep disorder; gastrointestinal symptom; delusion; nonhuman; placebo; interferon; alpha interferon; drug withdrawal; Hamilton scale; hepatitis C; Hepatitis C; irritability; screening test; mania; side effect; hypomania; escitalopram; milnacipran; ribavirin; low drug dose; diaphoresis; hypothyroidism; Beck Depression Inventory; dizziness; alpha2a interferon; alpha2b interferon; cytokine; peginterferon; peginterferon alpha2a; peginterferon alpha2b; thyroid disease; gamma interferon; recombinant interferon; anticholinergic syndrome; Montgomery Asberg Depression Rating Scale; drug induced headache; Pegylated interferon; interleukin 1